ACM
Aquilo Capital Management Portfolio holdings
AUM
$37.1M
This Quarter Return
-0.51%
1 Year Return
-36.49%
3 Year Return
+1.32%
5 Year Return
+39.69%
10 Year Return
–
AUM
$367M
AUM Growth
+$367M
(+9.4%)
Cap. Flow
+$56.6M
Cap. Flow
% of AUM
15.43%
Top 10 Holdings %
Top 10 Hldgs %
89.26%
Holding
19
New
1
Increased
11
Reduced
1
Closed
1
Top Buys
| 1 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$32.5M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$12.2M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$8.95M |
| 4 |
uniQure
QURE
|
$8.54M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$4.18M |
Top Sells
| 1 |
AnaptysBio
ANAB
|
$26.1M |
| 2 |
Spero Therapeutics
SPRO
|
$1.52M |
Sector Composition
| 1 | Healthcare | 88.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Spero Therapeutics
SPRO
$116M
| $56.4M | 10.19% |
3,829,209
-103,000
| -3% | -$1.52M |
|
|
DRNA
2
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $43.6M | 7.88% |
1,705,392
+350,000
| +26% | +$8.95M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $41.1M | 7.43% |
423,012
+43,000
| +11% | +$4.18M |
|
|
NGM
4
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $32.7M | 5.91% |
1,124,237
+118,703
| +12% | +$3.45M |
|
|
HARP
5
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $32.5M | 5.88% |
+1,554,199
| New | +$32.5M |
|
|
6
uniQure
QURE
$896M
| $32.2M | 5.82% |
955,424
+253,374
| +36% | +$8.54M |
|
7
Dianthus Therapeutics
DNTH
$759M
| $29.6M | 5.35% |
2,502,210
+235,787
| +10% | +$2.79M |
|
8
Arrowhead Research
ARWR
$3.05B
| $27.1M | 4.89% |
407,926
+42,000
| +11% | +$2.79M |
|
9
Regenxbio
RGNX
$451M
| $19.1M | 3.45% |
559,444
+56,000
| +11% | +$1.91M |
|
|
10
4D Molecular Therapeutics
FDMT
$288M
| $13.1M | 2.36% |
300,886
+280,886
| +1,404% | +$12.2M |
|
|
AMYT
11
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $11.1M | 2.01% |
800,000
| – | – |
|
|
PVLA
12
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $9.45M | 1.71% |
3,675,530
| – | – |
|
13
Galapagos
GLPG
$2.07B
| $9M | 1.63% |
116,723
+46,734
| +67% | +$3.6M |
|
14
argenx
ARGX
$43.6B
| $5.84M | 1.06% |
21,200
+8,500
| +67% | +$2.34M |
|
15
Genmab
GMAB
$15.3B
| $3.94M | 0.71% |
120,000
+30,000
| +33% | +$985K |
|
|
16
AnaptysBio
ANAB
$569M
| – | – |
-1,215,958
| Closed | -$26.1M |
|
17
iShares Biotechnology ETF
IBB
$5.6B
| – | – |
0
| – | – |
|
18
SPDR S&P 500 ETF Trust
SPY
$658B
| – | – |
0
| – | – |
|
19
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – |
0
| – | – |
|